Arecor Therapeutics (LSE:AREC) FCF Margin % : -51.62% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Arecor Therapeutics's Free Cash Flow for the six months ended in Dec. 2023 was £-1.50 Mil. Arecor Therapeutics's Revenue for the six months ended in Dec. 2023 was £2.90 Mil. Therefore, Arecor Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -51.62%.

As of today, Arecor Therapeutics's current FCF Yield % is -13.35%.

The historical rank and industry rank for Arecor Therapeutics's FCF Margin % or its related term are showing as below:

LSE:AREC' s FCF Margin % Range Over the Past 10 Years
Min: -476.6 Med: -237.84 Max: -37.48
Current: -131.03

During the past 7 years, the highest FCF Margin % of Arecor Therapeutics was -37.48%. The lowest was -476.60%. And the median was -237.84%.

LSE:AREC's FCF Margin % is ranked better than
51.24% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs LSE:AREC: -131.03

Arecor Therapeutics FCF Margin % Historical Data

The historical data trend for Arecor Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics FCF Margin % Chart

Arecor Therapeutics Annual Data

Trend

May17

May18

May19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-344.65

-112.43

-476.60

-462.96

-131.03

Arecor Therapeutics Semi-Annual Data
	May18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial					-481.71	-642.71	-390.12	-269.20	-51.62

Competitive Comparison of Arecor Therapeutics's FCF Margin %

For the Biotechnology subindustry, Arecor Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arecor Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's FCF Margin % falls into.

Arecor Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Arecor Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-5.992	/	4.573
	=	-131.03 %

Arecor Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.499	/	2.904
	=	-51.62 %

Arecor Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

6UI:Germany

Address

Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL

Website

https://www.arecor.com

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.